A phase II study of DS-1001 in patients with chemotherapy- and radiotherapy-naïve IDH1 mutant WHO grade 2 gliomas is ongoing to verify the efficacy of DS-1001 as a single agent (NCT04458272). This evidence concerns the gene IDH1 and glioma.